LEAMINGTON, Ontario, Feb.
17, 2022 – PRESS RELEASE – Tilray
Brands Inc., a leading global cannabis-lifestyle and consumer packaged
goods company focused on inspiring and empowering the worldwide community to
live its very best life, announced that its medical cannabis division, Tilray
Medical, has completed its first sale of medical cannabis in Malta.
Tilray’s EU-GMP medical cannabis products are now available in pharmacies
across Malta,
providing patients with safe and reliable access to high-quality medical
cannabis.
Denise Faltischek, Tilray’s chief strategy officer
and head of International Business, said, “As demand for cannabis continues to
grow across Europe,
we’re incredibly proud to partner with established and reliable distribution
partners to supply new markets with high-quality medical cannabis which
patients can rely on.”
In Malta,
patients may obtain prescriptions for medical cannabis and a medical cannabis
card through family doctors. Medical cannabis cards are issued by Malta’s Office
of the Superintendence of Public Health.
Tilray has a pioneering track record as a
company committed to making EU GMP-certified, pharmaceutical-grade medical
cannabis products available to patients in need around the world and was the
first to successfully export medical cannabis from North
America and import medical cannabis products into the EU in
2016.
